Drug Development

With a major FDA decision pending, Aquestive Therapeutics pitches its game-changing anaphylaxis film, Anaphylm, to Wall Street's top healthcare investors.

Saol Therapeutics' NDA resubmission isn't just a second chance; it's a calculated maneuver signaling a new playbook for navigating the FDA in rare disease.

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

A UK spinout just raised £2M for an eye-drop that becomes a healing bandage on contact. This could disrupt a $12B market and offer hope for rare diseases.

With a promising osteoarthritis drug in late-stage trials, Levicept hires a CFO known for Nasdaq listings and M&A, signaling a major financial move.

Aligos Therapeutics secures a key partnership and regulatory fast-track in China, signaling a major financial and clinical validation for its novel HBV drug.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

With a breakthrough oral drug for a rare form of blindness, Belite Bio heads to a key symposium. Can it convince investors it can win a crowded race?

Invivyd's COVID-19 drug PEMGARDA loses its emergency status, sparking a high-stakes race for full approval and raising fears of a looming gap in patient care.

VERAXA Biotech is betting its future on its proprietary BiTAC technology, a strategic pivot that sharpens its focus amid a volatile market for cancer therapies.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

A new partnership aims to use tiny, fully human antibodies to shuttle drugs past the blood-brain barrier, a move that could unlock a new era of treatments.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

An inside look at how Chengdu is pairing high-tech industrial might with aggressive global outreach to redefine itself as a critical node in tech and biotech.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.